Endocrine therapy for breast cancer patients with ER and PR turning positive after neoadjuvant chemotherapy
10.3760/cma.j.issn.1007-631X.2010.12.008
- VernacularTitle:新辅助化疗后ER、PR阳性表达乳腺癌患者的内分泌治疗
- Author:
Xiaoqing GUAN
;
Ji WU
;
Yan CHEN
;
Shucheng GU
;
Jianqiang WU
;
Jisheng WU
;
Mu YUAN
;
Xiaohong SHI
;
Xiaoling JIANG
;
Lifeng GE
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Antineoplastic combined chemotherapy protocols;
Receptors,estrogen;
Receptors,progesterone;
Endocrine therapy
- From:
Chinese Journal of General Surgery
2010;25(12):963-965
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of endocrine therapy in breast cancer patients whose estrogen receptor (ER) and progesterone receptor(PR) was preoperatively negative and turned positive after neoadjuvant chemotherapy. Methods The clinical experimental study was carried out in 97 cases of breast cancer which were divided into endocrine treatment group and control group. The follow-up time ranged from 15 to 60 months. Results In endocrine treatment group, 3 and 5-year disease-free survival were respectively 74.5% (38/51), 60.7% (31/51), and 3 and 5-year overall survival were respectively 80%(41/51), 74. 5% (38/51). In control group, 3 and 5-year disease-free survival were respectively 54.2% (26/46), 41.7%(20/46), and 3 and 5-year overall survival were 60.9%(28/46),50%(23/46),respectively. The corresponding values were significantly higher in endocrine treatment group than in control group(P＜0.05).Conclusions Remedy endocrine therapy improves the disease-free and overall survival rate in breast cancer patients with the expression of ER and PR turning positive after initial neoadjuvant chemotherapy.
